ProtoKinetix Announces Acquisition of Patents
April 07 2015 - 1:59PM
Business Wire
ProtoKinetix, Incorporated (OTC:
PKTX) (www.protokinetix.com) (“ProtoKinetix” or the “Company”) is
pleased to announce that it has completed the acquisition of
certain patents and all rights associated therewith (the “Patents”)
from Institut National des Sciences Appliquées de Rouen (“INSA”)
pursuant to an Assignment of Patents and Patent Application (the
“Patent Assignment”) entered into on or about January 5, 2015.
ProtoKinetix made payment of 25,000 Euros to INSA for all of the
Patents and rights associated therewith, for the “Gem
difluorinated C-glycopeptides, their preparation and their use for
the preservation of biological materials and/or in cryosurgery”
family of patents, which includes issued patents in Canada (Patent
No. CA2,558,801), England, France, and Germany (Patent No.
EP1,817,329) and the United-States (Patent No. US8,394,362). These
Patents secure, amongst other things, key intellectual property
rights to the Company’s AAGP™ lead compound.
By securing these Patents, the Company is in a better position
to move forward with its operations. “We are pleased to secure the
rights to these Patents as we can now license the rights to other
companies to develop different applications of the AAGP™ lead
compound,” said Clarence E. Smith, President and Chief Executive
Officer.
About ProtoKinetix
ProtoKinetix, Inc. is a molecular biotechnology company that has
developed and patented a family of hyper stable, potent
glycopeptides (AAGP™) that dramatically enhance therapeutic results
and reduce the cost of stem cell medicine. Due to the
anti-inflammatory effect of AAGP™ molecules, the Company is
currently targeting the direct treatment of diseases that have a
major inflammatory component.
Cautionary Statement Regarding Forward-Looking Information
Except for statements of historical fact, this news release
contains certain “forward-looking information” within the meaning
of applicable securities law, including statements regarding the
Company's intention to license the Patent rights to third parties
and the potential treatments for which the Company's AAGPTM may be
applied. Forward-looking information is frequently characterized by
words such as “plan”, “expect”, “project”, “intend”, “believe”,
“anticipate”, “estimate” and other similar words, or statements
that certain events or conditions “may” or “will” occur.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those anticipated in the forward-looking statements. The Company
undertakes no obligation to update forward-looking information if
circumstances or management’s estimates or opinions should change
except as required by law. The reader is cautioned not to place
undue reliance on forward-looking statements. More detailed
information about potential factors that could affect financial
results is included in the documents filed by the Company from time
to time with the United States Securities Commission and with
securities regulatory authorities in Canadian on SEDAR.
The Private Securities Litigation Reform Act of 1995 provides a
“safe harbor” for forward-looking statements. Some information
included in this press release contains statements that are
forward-looking. Such forward-looking information involves
significant risks and uncertainties that could affect anticipated
results in the future and, accordingly, these results may differ
materially from those expressed in any forward-looking statements
made by or on behalf of the Company. For a description of
additional risks and uncertainties, please refer to the Company’s
filings with the Securities and Exchange Commission.
Clarence E. Smith – President and CEO
ProtoKinetix, Inc.Clarence E. Smith, President & Chief
Executive Officer304-299-5070csmith@protokinetix.com
Protokinetix (PK) (USOTC:PKTX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Protokinetix (PK) (USOTC:PKTX)
Historical Stock Chart
From Nov 2023 to Nov 2024